{"groups":[{"description":"Nivolumab 360 mg Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery; then post surgery nivolumab 480 mg Q4W adjuvant treatment for up to 13 cycles (approximately 1 year)","id":"FG000","title":"Nivolumab + SOC Chemotherapy"},{"description":"Placebo Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery, then post-surgery placebo Q4W for up to 13 cycles (approximately 1 year).","id":"FG001","title":"Placebo + SOC Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant no longer met study criteria"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"229"},{"groupId":"FG001","numSubjects":"232"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"228"},{"groupId":"FG001","numSubjects":"230"}],"comment":"Continued to treatment period","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Randomization"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"8"}],"type":"Ongoing treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"72"}],"type":"Disease progression/recurrence"},{"reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"13"}],"type":"Study drug toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"14"}],"type":"Adverse event unrelated to study drug"},{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"8"}],"type":"Participant request to discontinue study treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Participant withdrew consent"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}],"type":"Participant no longer meets study criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"17"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Administrative reason by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Not reported"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"228"},{"groupId":"FG001","numSubjects":"230"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"228"},{"groupId":"FG001","numSubjects":"230"}],"type":"Neoadjuvant Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"142"},{"groupId":"FG001","numSubjects":"152"}],"type":"Adjuvant Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"85"},{"groupId":"FG001","numSubjects":"92"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"143"},{"groupId":"FG001","numSubjects":"138"}],"type":"NOT COMPLETED"}],"title":"Treatment"}]}